|
|
|
|
|
|
|
|
|
|
|
|
|
02.02.26 - 12:54
|
IDEXX Laboratories Inc Bottom Line Climbs In Q4 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - IDEXX Laboratories Inc (IDXX) announced a profit for its fourth quarter that Increased, from the same period last yearThe company's earnings totaled $248.188 billion, or $3.......
|
|
|
|
|
02.02.26 - 12:33
|
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic.
Strong organic growth benefits from IDEXX execution and commercial performance, including over 1,900 IDEXX inVue Dx™ placements, delivering a quarterly record of instrument placements and 12% year-over-year expansion of IDEXX's global premium instrument installed base.
Delivers fourth quarter EPS of $3.08, an increase of 18% as reported and 17% on a comparable basis, supported by operating margin expansion of 150 basis points as reported and 120 basis points on a comparable basis.
Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million, reflecting growth of 7.6% - 9.6% reported and 7.0% - 9.0% organic, led by CAG Diagnostics recurring revenue growth of 8.6% - 10.6% as reported and 8.0% - 10.0% on an organic basis.
Projects 2026 EPS of $14.29 - $14.80, an increase of 9% - 13% as reported and 10% - 14% on ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 14:33
|
IDEXX Announces CEO Succession (Business Wire)
|
|
|
Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of DirectorsWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX's Board of Directors (the “Board”). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Company's annual meeting of shareholders in May 2027, and will work closely with Dr. Erickson throughout this extended period to support a seamless transition. Dr. Erickson will also join the Board, effective upon his assumption of the role of President and CEO.
Dr. Erickson brings nearly two decades of leadership experience and significant healthcare technology and innovation expertis...
|
|
|
09.01.26 - 19:36
|
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results (Business Wire)
|
|
|
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.
The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 263206.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, c...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
